TIM3KO WT1-TCR engineered T cells

TIM3KO WT1-TCR engineered T cells are an adoptive cell therapy consisting of T cells genetically modified to express a T-cell receptor (TCR) specific for the Wilms Tumor 1 (WT1) antigen, restricted by HLA-A*02:01. To overcome immunosuppression within the tumor microenvironment, these cells incorporate a CRISPR-mediated knockout of the inhibitory receptor TIM-3 (Hepatitis A virus cellular receptor 2). This dual-pronged strategy is designed to enhance the persistence and cytotoxic activity of the engineered T cells against WT1-positive tumors, such as epithelial ovarian cancer. Preclinical studies have demonstrated that the disruption of the TIM-3 pathway shields the T cells from exhaustion and improves their ability to induce apoptosis in tumor organoids and primary cultures. The therapy is being developed through a collaboration between the San Raffaele Scientific Institute and Intellia Therapeutics.

Other names

TIM3-knockout WT1-specific TCR-engineered T cellsTIM-3-knockout WT1-specific TCR-engineered T cellsTIM 3-knockout WT1-specific TCR-engineered T cellsTIM3KO WT1-TCR T cellsTIM-3KO WT1-TCR T cellsTIM 3KO WT1-TCR T cells